MEDISPA.PRO
Ministry of Health code: A11.12.003 Axis M0 · Introductory check-up and longevity biomarkers CEBM: Level A (Infusion therapy (IV therapy))

Intravenous targeted infusion of ferric carboxymaltose (Ganzoni protocol)

Intravenous Ferric Carboxymaltose Infusion

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
60 min
Turnover: ~75 min
Recommended course
7 sessions
1–2 infusions 7 days apart (course dose per the Ganzoni formula)
Throughput capacity
6 pts
per 8-hour shift
Median rate
11 000 ₽
7 500 ₽ – 13 550 ₽
Course cost
77 000 ₽
at market median
Publication volume
Level A
12 publ. in PubMed

Clinical profile

Intravenous administration of iron preparations (carboxymaltose, derisomaltose) for iron deficiency when oral iron does not help or is not tolerated. Benefit is proven in iron-deficiency anaemia of pregnancy and in heart failure with iron deficiency; risks include hypersensitivity, hypophosphataemia and infections.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Mechanism of action

  • Ferric carboxymaltose rapidly raises active FGF23, leading to renal phosphate wasting, calcitriol deficiency and secondary hyperparathyroidism. [12]

Where studies show an effect

  • Iron-deficiency anaemia of pregnancy: intravenous iron probably raises haemoglobin and reduces anaemia slightly more than oral iron (Cochrane). [1]
  • A single infusion in anaemia of pregnancy: fewer low-birth-weight babies and more often normal haemoglobin achieved without additional treatment. [6]
  • Heart failure with iron deficiency: a meta-analysis showed fewer cardiovascular events, especially in the first year. [2]
  • After hospitalisation for acute heart failure: fewer rehospitalisations, with no effect on cardiovascular mortality. [3]
  • Marked fatigue after postpartum haemorrhage: a single dose of iron reduced physical fatigue more than oral iron. [7]

Open questions and study limitations

  • In the large HEART-FID and FAIR-HF2 RCTs, ferric carboxymaltose did not reduce mortality or hospitalisations in patients with heart failure. [4, 5]
  • The clinical significance of the more frequent hypophosphataemia after carboxymaltose requires study. [10, 11]

Safety

  • Intravenous iron is associated with an increased risk of infection (meta-analysis). [8]
  • The risk of hypersensitivity reactions is higher with a previous reaction, rapid infusion, multiple drug allergies or severe atopy; early pregnancy is a contraindication. [9]
  • Ferric carboxymaltose causes hypophosphataemia more often than ferric derisomaltose. [10, 11]

Protocol in studies

  • In anaemia of pregnancy, a single infusion of carboxymaltose or derisomaltose was used. [6]
  • Infusion requires close monitoring and trained staff ready to give immediate help in case of a reaction. [9]
Contraindications. Early pregnancy is a contraindication to iron infusions; other contraindications are determined by the physician according to the drug instructions.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
B.Braun Perfusor Space infusion pump / Mindray vital signs monitor

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
B.Braun Perfusor Space infusion pump
Medical device, Roszdravnadzor registration certificate / CE
In the registry →
Mindray vital signs monitor
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.1 120.0 m² · Class B

Treatment room for intravenous infusions / treatment room / laser blood irradiation / ozone therapy room / blood UV irradiation (10 individual cubicles)

General therapeutic interventions and high-tech therapy · Equipment: 11 538 900 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) 7 500 ₽
Market median 11 000 ₽
75th percentile (P75) 13 550 ₽

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Prices for this procedure appear in the price lists of 3 industry facilities; the median and interquartile range across facilities are shown (each facility counts once).

Evidence base

A Cochrane review and meta-analyses of RCTs confirm the effect in anaemia of pregnancy and heart failure, but large RCTs in HF gave mixed results; the risk profile is well described.

Publication level A · Plenty of data
  1. 1.
    Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy.
    Cochrane Database Syst Rev, 2024 · Cochrane systematic review · PMID 39651609
    Anaemia of pregnancy: intravenous iron is probably slightly better than oral iron for haemoglobin and anaemia; data on adverse effects are incomplete.
  2. 2.
    Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency.
    Nat Med, 2025 · Systematic review and meta-analysis · PMID 40159279
    Heart failure with iron deficiency: intravenous iron reduces cardiovascular events and is safe; the effect is greater in the first year.
  3. 3.
    Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Lancet, 2020 · RCT, double-blind (AFFIRM-AHF) · PMID 33197395
    After acute heart failure, ferric carboxymaltose reduced the risk of rehospitalisation; mortality was unchanged.
  4. 4.
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    N Engl J Med, 2023 · RCT (HEART-FID) · PMID 37632463
    Outpatients with HFrEF: no difference from placebo in death, hospitalisations or walk test.
  5. 5.
    Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.
    JAMA, 2025 · RCT (FAIR-HF2) · PMID 40159390
    Ferric carboxymaltose did not reduce the time to first hospitalisation or cardiovascular death.
  6. 6.
    Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial.
    Am J Obstet Gynecol, 2025 · RCT, multicentre · PMID 39909327
    A single iron infusion in anaemia of pregnancy: fewer low-birth-weight babies and more often normal haemoglobin without additional treatment.
  7. 7.
    Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage.
    J Matern Fetal Neonatal Med, 2019 · RCT · PMID 29558233
    Fatigue after postpartum haemorrhage: a single dose of iron isomaltoside significantly reduced physical fatigue.
  8. 8.
    Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis.
    JAMA Netw Open, 2021 · Systematic review and meta-analysis · PMID 34767026
    Intravenous iron is associated with an increased risk of infection.
  9. 9.
    Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.
    Haematologica, 2014 · Meta-analysis and recommendations · PMID 25420283
    Risk factors for hypersensitivity reactions and how to prevent and treat them; early pregnancy is a contraindication.
  10. 10.
    Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    JAMA, 2020 · Two RCTs (PHOSPHARE) · PMID 32016310
    Derisomaltose caused hypophosphataemia less often than carboxymaltose.
  11. 11.
    Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Gut, 2023 · RCT · PMID 36343979
    In IBD, ferric carboxymaltose caused hypophosphataemia more often, with equal efficacy in treating anaemia.
  12. 12.
    Randomized trial of intravenous iron-induced hypophosphatemia.
    JCI Insight, 2018 · RCT · PMID 30518682
    Carboxymaltose raises FGF23, which triggers phosphate loss and secondary hyperparathyroidism.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.